Are you eager to use your immunology expertise and in vivo preclinical experience to have impact on the development of new drugs?
Your new role
As scientist in the In Vivo Pharmacology, Toxicology and DMPK Department within Byondis’ Preclinical Research you will help drive our drug development efforts in immuno-oncology (IO). After building a deep understanding of the disease and biology around the therapeutic target, you will design preclinical in vivo studies to evaluate disease response, resistance and mechanisms of action and to demonstrate proof of principle of novel therapeutic candidates. You will outsource these studies to and collaborate with international contract research organizations and academic institutes.
For immunology-based questions related to in vivo models, you will be the source of information and subject matter expert within your department. You will set-up IO animal models that enable you to efficiently test new concepts and compounds, monoclonal antibodies and/ or antibody-drug conjugates in vivo. Your output includes proposing clear hypotheses, design and execution of clever experiments, interpretation and presentation of data in oral presentations, internally and occasionally externally at conferences but also in writing as internal reports, sections of regulatory filings and scientific papers. You will represent your department in multi-disciplinary teams.
What you will need to succeed
Candidates must have a PhD in a field of immunology and experience in basic or translational research either in an academic and/or industry setting. Experience with immunologically humanized mouse models, immune cell activation and/or characterization of tumors using FACS analysis is a plus. You must demonstrate a high level of independence and be able to develop hypotheses, translate these into focused experiments and execute these, based on a thorough understanding of disease and drug target biology. You have ample experience with in vivo experimentation and a strong commitment to the principles of the 3Rs (Replacement, Reduction and Refinement). The position requires working in close partnership across various disciplines and with external partners. Thus, strong communication skills are required, as evidenced by publications, meeting abstracts and/or contributions to regulatory documents. You have a proven track record of solving preclinical immunological research questions and as team player in a multidisciplinary team.
Byondis’ broad development portfolio comprises preclinical and early- and late-stage clinical programs, including the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985, Phase III). The company has a dedicated team of more than 350 staff including highly educated scientists and skilled technicians working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. Byondis collaborates with global biotechnology and pharmaceutical companies and national and international academic research institutions and we offer you a dynamic and multidisciplinary working environment where your skills like a creative mind and critical view are fully in place.
Information and application
Contract hours: 32-40 hrs/week. Flexible working arrangements
Salary: Competitive salary with benefits
Required start date: ASAP
First interviews will be scheduled on 1/09/2021 and second interviews on 7/09/2021
What you need to do
If you are interested in this role, 'click' apply to forward your up-to-date CV with a short motivational letter
For further information, please contact Penny de Villiers